[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100448132":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":63,"collaborators":65,"id":68,"slug":32,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":32,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":32,"enrollmentInfo":76,"targetDuration":32,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":37,"whyStopped":32,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening MRI","EXPERIMENTAL","Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.",[13],"Diagnostic Test: Magnetic Resonance Imaging",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Magnetic Resonance Imaging","Participants will undergo MRI imaging with and without contrast.",[9],[21],"MRI",[23],{"name":24,"affiliation":25,"role":26},"Kamran A Ahmed, MD","Moffitt Cancer Center","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Robin Dowell","CONTACT","813-745-0393",null,"Robin.Dowell@moffitt.org",[35,54],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Morton Plant Mease- Baycare","RECRUITING","Clearwater","Florida","33756","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-82.8001,27.96585,{"lat":47,"lon":46},[50,53],{"name":51,"role":30,"phone":32,"phoneExt":32,"email":52},"Ronica H. Nanda, MD","Ronica.Nanda@baycare.org",{"name":51,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":25,"status":55,"city":56,"state":39,"zip":57,"country":41,"countryCode":42,"cosmosGeoPoint":58,"geoPoint":62,"contacts":32},"ACTIVE_NOT_RECRUITING","Tampa","33612",{"type":44,"coordinates":59},[60,61],-82.45843,27.94752,{"lat":61,"lon":60},{"type":64,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[66],{"name":67,"class":6},"Florida Breast Cancer Foundation","100448132",false,"NCT05115474","Study of Screening Brain MRIs in Stage IV Breast Cancer","Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer","Inclusion Criteria:\n\n* Histologic diagnosis of breast cancer with documentation of ER\u002FPR\u002FHER2 status\n* Radiographic evidence of stage IV extracranial diease having progressed past first line therapy in HR+\u002FHER2- patients\n* Radiographic evidence of stage IV extracranial disease in TN and HER2+ patients\n* Age ≥ 18\n* Life expectancy ≥ 6 months\n* Eastern Cooperative Oncology Group performance status 0 to 2\n* Patients must be able to understand and the willingness to sign an informed consent for study procedures\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Prior diagnosis or treatment of brain metastases or leptomeningeal disease\n* Patients with prior history of non-breast cancer malignancies should have no evidence of disease ≥ 2 years\n* Neurologic symptoms warranting standard screening brain MRI in the judgement of the treating physician at time of enrollment\n* Indications warranting brain MRI for other neurologic conditions at time of study entry\n* Contraindication towards MRI imaging with contrast\n* Chronic kidney disease stage IV or V or end stage renal disease","ALL","18 Years",{"count":77,"type":78},170,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.",[84,85,86],"Triple Negative Breast Cancer","HER2-positive Breast Cancer","Hormone Receptor-positive Breast Cancer",[88],"Stage IV Breast Cancer","2026-05-14",{"date":91,"type":92},"2026-05-18","ACTUAL",{"date":94,"type":92},"2021-12-21",{"date":96,"type":78},"2026-10",{"name":5,"class":6},2]